{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:43:44Z","timestamp":1770741824078,"version":"3.49.0"},"reference-count":13,"publisher":"American Society of Consultant Pharmacists","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:p>Three drugs are discussed in this article: finerenone, difelikefalin, and avacopan. Finerenone (Kerendia\u2122) is FDA-indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end stage kidney disease (ESKD), cardiovascular (CV) death, non-fatal\n myocardial infarction (MI), and hospitalization for heart failure (HF) in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Difelikefalin (Korsuva\u2122) is FDA-indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney\n disease (CKD-aP) in adults undergoing hemodialysis (HD). Avacopan (Tavneos\u2122) is FDA-indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic\n polyangiitis [MPA]) in combination with standard therapy including glucocorticoids.<\/jats:p>","DOI":"10.4140\/tcp.n.2022.130","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T15:54:36Z","timestamp":1648223676000},"page":"130-138","source":"Crossref","is-referenced-by-count":3,"title":["New Drugs Update: Finerenone, Difelikefalin, and Avacopan"],"prefix":"10.4140","volume":"37","author":[{"given":"Lana","family":"Gettman","sequence":"first","affiliation":[{"name":"Harding University, Searcy Arkansas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"key":"ref1","volume-title":"Novel Drugs Approvals for 2021: KerendiaTM (finerenone)."},{"key":"ref2","year":"2021"},{"issue":"Suppl 1","key":"ref3","first-page":"S15","article-title":"Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021 [published correction appears in Diabetes Care.","volume":"44","year":"2021","journal-title":"Diabetes Care."},{"key":"ref4","volume-title":"Estimates of Diabetes and Its Burden in the United States.","year":"2020"},{"key":"ref5","article-title":"Wolters Kluwer Health, Inc.","year":"2021"},{"key":"ref6","year":"2021","journal-title":"Novel Drugs Approvals for 2021: KorsuvaTM (difelikefalin) injections, for intravenous use Inital U.S. Approval: 2021."},{"key":"ref7"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1093\/ndt\/gfl461","article-title":"Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Ptterns Study (DOPPS).","volume":"21","year":"2006","journal-title":"Nephrol Dial Transplant."},{"key":"ref9","first-page":"1","article-title":"Clinical characteristics and outcomes of end-stage renal disease patients wiht self-reported pruritus symptoms.","volume":"7","year":"2014","journal-title":"Int J Nephrol Renovasc Dis."},{"issue":"1","key":"ref10","first-page":"42","article-title":"Self-reported pruritus and clinical, dialysis-related, and patieint-reported outcomes in hemodialysis patients.","volume":"3","year":"2020","journal-title":"Kidney Med."},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2215\/CJN.00100110","article-title":"A longitudinal study of Uremic Pruritus in hemodialysis patients.","volume":"5","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"ref12","volume-title":"Novel Drugs Approvals for 2021: TavenosTM(Avacopan)."},{"key":"ref13","first-page":"2021","volume":"8","year":"2021","journal-title":"Accessed December"}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2022\/00000037\/00000004\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T04:31:03Z","timestamp":1651033863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2022.130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"alternative-id":["2639-9636(20220401)37:4L.130;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2022.130","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}